Market Signal Briefing

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

PLEASANTON, CA / ACCESS Newswire / October 14, 2025 / The market always appreciates a great company story. The problem is that it often rewards the ones that sound big, not necessarily the ones that are big.

, /PRNewswire/ -- Diebold Nixdorf (NYSE: DBD), a world leader in transforming the way people bank and shop, will release third quarter 2025 financial results on Wednesday, Nov. 5, before trading begins on the New York Stock Exchange. Octavio Marquez, president and chief executive officer, and Tom Timko, executive vice president and chief financial officer, will discuss the results during a conference call and webcast that day beginning at 8:30 a.m. ET.

Earnings Call Details:

Date: Wednesday, Nov. 5
Time: 8:30am ET
Webcast: Diebold Nixdorf Q3 2025 Earnings Webcast

Prior to the call, Diebold Nixdorf will provide a press release summarizing business and financial results, and a presentation containing other highlights from the period. The press release and presentation will be accessible by visiting the Investor Relations section of Diebold Nixdorf's website located at http://www.dieboldnixdorf.com/earnings. Live access to the webcast of the conference call, as well as the replay, will also be available on this website.

Registration for the earnings call is available here. After registering, you will receive an individualized dial-in number and PIN. To avoid wait times, we suggest registering at least one day in advance. Registration will be open throughout the live call. We encourage participants to dial in approximately 10 minutes before the start of the earnings call.

About Diebold Nixdorf
Diebold Nixdorf, Incorporated (NYSE: DBD) automates, digitizes and transforms the way people bank and shop. As a partner to the majority of the world's top 100 financial institutions and top 25 global retailers, our integrated solutions connect digital and physical channels conveniently, securely and efficiently for millions of consumers each day. The company has a presence in more than 100 countries with approximately 21,000 employees worldwide. Visit www.DieboldNixdorf.com for more information.

LinkedIn: www.linkedin.com/company/diebold
X: https://x.com/DieboldNixdorf
Facebook: www.facebook.com/DieboldNixdorf
YouTube: www.youtube.com/dieboldnixdorf

SOURCE Diebold Nixdorf, Incorporated

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Verisk’s first-of-its-kind program offers insurers policy forms, rating rules and loss costs

October 14, 2025 08:15 ET

 | Source:

Verisk Analytics, Inc.

JERSEY CITY, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Verisk (Nasdaq: VRSK), a leading strategic data analytics and technology partner to the global insurance industry, today announced the launch of a pet health insurance program within its Core Lines business. The first-of-its-kind program offers U.S. insurers a robust suite of standardized tools and insights to support entry into or expansion within the rapidly growing pet insurance market.

Verisk’s new ISO Pet Insurance Line of Business program will offer insurers policy forms, rating rules and loss costs, marking the first standardized pet insurance program from an advisory organization.

“As more people have welcomed pets into their lives, the demand for pet insurance has surged in recent years along with veterinary costs,” said Ron Beiderman, chief product officer, Core Lines at Verisk. “With our new program, insurers have the tools and insights to support this growing market, reduce complexities and bring innovative coverage options to market faster, giving pet parents peace of mind.”

Meeting a Growing Market Need

The U.S. pet insurance market reached nearly $4.75 billion in gross written premiums in 2024, reflecting a 21.4 percent year-over-year increase, according to the 2025 NAPHIA State of the Industry Report. The number of insured pets also grew by 12.7 percent.

Verisk’s new Pet Line of Business Hub, available on its core.verisk.com platform, offers:

Actuarially sound advisory loss costs and territorial rating tools that incorporate geography, breed, age and other factors to access risk accurately and appropriately.An accident and illness policy form and related endorsements to help insurers provide adequate coverage. Monitoring and compliance updates via Verisk’s Pet Legislation Dashboard which provides state-specific legislation comparisons and NAIC Pet Insurance Model Law analysis. Driving Innovation and Accessibility

The lack of a standardized advisory program has been a barrier for many insurers, due to market complexities that lead to lower adoption rates and higher churn for policyholders as well as regulatory fragmentation. Verisk’s solution addresses this gap, enabling more carriers to offer pet insurance and contribute to a more competitive and accessible market.

Beiderman added: “Pet insurance is no longer a niche offering. Verisk’s new program helps insurers serve policyholders with empathy and precision, while helping protect the pets they cherish.”

To learn more, please visit Verisk’s Pet Line of Business hub.

Verisk’s Underwriting & Rating Solutions helps global insurers, reinsurers and other stakeholders modernize their processes, reduce operating costs and underwrite risks quickly and precisely. These solutions support (re)insurers across multiple lines of business, including personal & commercial property, personal & commercial auto, small commercial and general liability programming to streamline forms, rules, loss costs and rating-related information. 

###

About Verisk 
Verisk (Nasdaq: VRSK) is a leading strategic data analytics and technology partner to the global insurance industry. It empowers clients to strengthen operating efficiency, improve underwriting and claims outcomes, combat fraud and make informed decisions about global risks, including climate change, extreme events, sustainability and political issues. Through advanced data analytics, software, scientific research and deep industry knowledge, Verisk helps build global resilience for individuals, communities and businesses. With teams across more than 20 countries, Verisk consistently earns certification by Great Place to Work and fosters an inclusive culture where all team members feel they belong. For more, visit Verisk.com and the Verisk Newsroom. 

Contact Data

Morgan Hurley
Verisk
551-655-7858
[email protected]

Major release of Oracle's flagship database architects AI into its core, seamlessly integrating AI across all major data types and workloads

Enables customers to achieve breakthrough insights, innovations, and productivity across multicloud and on-premises environments

New Oracle Autonomous AI Lakehouse supports the Apache Iceberg open table format, enabling customers to use the power of Oracle AI Database for their data lake data

, /PRNewswire/ -- Oracle AI World -- Oracle AI Database 26ai architects AI into the core of data management, furthering Oracle's commitment to help customers securely bring AI to all their data, everywhere. This milestone advances Oracle's "AI for Data" vision of a next-generation AI-native database with use of AI across the entire data and development stack, including AI Vector Search, AI for Database Management, AI for Data Development, AI for Application Development, and AI for Analytics. Customers can now run dynamic agentic AI workflows to provide sophisticated answers and actions that combine private database data with public information.

"By architecting AI and data together, Oracle AI Database makes 'AI for Data' simple to learn and simple to use," said Juan Loaiza, executive vice president, Oracle Database Technologies, Oracle. "We enable our customers to easily deliver trusted AI insights, innovations, and productivity for all their data, everywhere, including both operational systems and analytic data lakes."

Oracle's "AI for Data" strategy is open and ubiquitous. Oracle AI Database's built-in AI capabilities provide customers wide freedom of choice when building and deploying AI applications including support for: the Apache Iceberg open table format; Model Context Protocol (MCP); industry-leading LLMs; popular agentic AI frameworks; and Open Neural Network Exchange (ONNX) embedding models. Oracle AI Database's mission-critical functionality brings AI to data securely, efficiently, and reliably wherever it resides—Oracle Cloud, leading hyperscale clouds, private cloud, or on-premises.

Oracle AI Database implements NIST-approved quantum-resistant algorithms (ML-KEM) to encrypt data-in-flight. Combined with the existing support for quantum-resistant encryption for data-at-rest, Oracle AI Database's data protection approach is designed to prevent hackers from harvesting organizational data now and decrypting it using quantum computers later. Other vendors have implemented quantum-resistant algorithms either in their network and storage architectures or in their database services, but not both.

"Great AI needs great data. With Oracle AI Database 26ai, customers get both. It's the single place where their business data lives—current, consistent, and secure. And it's the best place to use AI on that data without moving it," said Holger Mueller, vice president and principal analyst, Constellation Research. "To help simplify and accelerate AI adoption, AI Database 26ai includes impressive new AI features that go beyond AI Vector Search. A highlight is Oracle's architecting Agentic AI into the database, enabling customers to build, deploy, and manage their own in-database AI agents using a no-code visual platform that includes pre-built agents. As Oracle's converged database leadership in transaction processing goes unchallenged, its leadership position in the data and AI space continues to rise sharply as well."

Oracle AI Database 26ai is a long-term support release that replaces Oracle Database 23ai. Customers can simply apply the October 2025 release update to transition from 23ai to the currently available features of 26ai. Customers will receive the immediately available features and will be ready for additional features as they are released. There is no database upgrade or application re-certification required. Advanced AI features such as AI Vector Search are included at no additional charge.

Oracle AI Database 26ai features that are planned include:

Enterprise-wide AI and Analytics

Oracle Autonomous AI Lakehouse: Supports the Apache Iceberg open table format, enabling true, enterprise-wide AI and analytics. It is now available on all four major hyperscalers—Oracle Cloud Infrastructure (OCI), Amazon Web Services, Microsoft Azure, and Google Cloud—and interoperable with Databricks and Snowflake on the same clouds. Autonomous AI Lakehouse enables customers to leverage their existing investments and gain the AI benefits of Autonomous AI Lakehouse for their business needs. Autonomous AI Lakehouse delivers Exadata-powered performance and pay-per-use serverless scaling. Learn more about Oracle Autonomous AI Lakehouse.

Foundational AI Technologies

Unified Hybrid Vector Search: Combines AI Vector Search with relational, text, JSON, knowledge graph, and spatial searches—allowing retrieval of related documents, images, videos, audio, and structured data. Customers can easily combine AI Vector Search with LLMs to search for private data that an LLM can combine with public data to answer business questions.
MCP Server Support: Enables AI Agents powered by LLMs to access an organization's database to answer questions using iterative reasoning. AI Agents can explore multiple solution paths and request additional data during their analysis to produce better and more accurate results.
Built-in Data Privacy Protection: Enforces sophisticated security, privacy, and compliance rules in the database. Measures include end-user-specific row, column, and cell-level data visibility as well as dynamic masking of unauthorized data. In addition, it helps AI to access the database directly using SQL or other APIs without exposing private data.
Oracle Exadata for AI: Accelerates AI at scale by delivering hardware and software engineered together for maximum performance and availability. Exadata can significantly accelerate AI vector queries by offloading them to Exadata intelligent storage. Vector offload also works with the new Exadata Exascale software architecture, which brings extreme elasticity and lower cost, extending Exadata benefits to smaller workloads and organizations. In addition, unique Remote Direct Memory Access (RDMA) algorithms further accelerate AI by enabling ultra low-latency and high-throughput data access from storage and across nodes in a cluster. Automatic data tiering delivers the low latency of memory, the high IOPS of flash, and the capacity of disk, while also reducing storage footprint using hybrid columnar compression (HCC). Finally, Exadata Database Service on Exascale Infrastructure supports Oracle Database 19c in OCI, Azure, and Google Cloud, enabling a much broader range of workloads to leverage Exadata's superior performance and scale.
Private AI Services Container: Provides a prebuilt and tested environment for running private instances of AI models such as embedding models, open-weight LLMs, and Named Entity Recognizers. Use of this container helps enhance AI workload security since customers can avoid sharing data with third-party AI providers. The container can be deployed anywhere the customer chooses, within the customer's tenancy in the public cloud, on private clouds, or on-premises.
AI Database Acceleration with NVIDIA: Oracle AI Database 26ai APIs that enable integration with LLM providers also support integration with NVIDIA NeMo Retriever microservices. Using this feature, Oracle AI Database 26ai can run vector embedding models or implement RAG pipelines using previously provisioned NVIDIA NIM microservices. In addition, Oracle Private AI Services Container, which currently supports execution on CPU resources, has also been designed to support the future use of NVIDIA accelerated computing for vector embedding and index generation using CAGRA (CUDA ANN GRAph-based algorithm) in the NVIDIA cuVS (GPU-Accelerated Vector Search) library.

AI for Application Development

Data Annotations: Help explain the purpose, characteristics, and semantics of data to AI. This additional information helps AI generate better applications and provide more accurate responses to natural language questions.
Unified Data Model: The relational, JSON, and graph data models have been unified, providing massive simplification. This accelerates developer productivity by enabling applications to access the same data in relational format via SQL, as a JSON document, or as a graph.
Select AI Agent: Build, deploy, and manage AI agents within Oracle Autonomous AI Database with a simple, secure, and scalable in-database framework. It supports custom and pre-built in-database tools, external tools via REST, and MCP servers, enabling the automation of multi-step agentic workflows, accelerating innovation, and helping organizations keep their data safe.
AI Private Agent Factory: Provides a no-code AI agent builder and deployment framework. These agents benefit from the full power, performance, scalability, and security of the converged data architecture of Oracle AI Database. It runs as a container in any environment of the customers' choosing to enhance data security—without customers having to share data with agentic frameworks on third-party clouds.
APEX AI Application Generator: To boost developer productivity, Oracle plans to deliver next generation APEX development tools that use natural language interfaces to provide trusted answers to user questions and to generate enterprise-grade business applications.

Mission-critical Innovations

Oracle Database Zero Data Loss Cloud Protect: Protects on-premises Oracle databases from data loss and ransomware using Oracle Zero Data Loss Recovery Service running in OCI. This includes real-time protection of database changes and enables fast recovery to any point-in-time.
Globally Distributed Database: Supports ultra-scalability and data sovereignty by enabling a single logical database to be split into multiple parts and stored on different servers. Built-in RAFT-based replication enables multi-master, active-active distributed databases to fail over with zero data loss in less than three seconds.
True Cache: Provides a unique application-transparent middle-tier cache that automatically ensures transactional consistency. Developers don't need to write code to populate and manage the data in the cache. True Cache brings the rich functionality of Oracle AI Database to mid-tier caches. All Oracle SQL, Vector, JSON, Spatial, and Graph query capabilities are also available via True Cache.
SQL Firewall: Delivers in-database scalable protection against unauthorized SQL activity and injection attacks, enhancing security for all data in the database.

Additional Resources

Watch Juan Loaiza's keynote at Oracle AI World
Read the technical blog about Oracle AI Database 26ai
Read what industry analysts are saying about Oracle AI Database 26ai

About Oracle
Oracle offers integrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud. For more information about Oracle (NYSE: ORCL), please visit us at oracle.com.

About Oracle AI World
Oracle AI World is where customers and partners discover the latest product and technology innovations, see how AI is being applied across industries, and connect with experts and peers. Attendees will gain practical tips and insights to drive immediate impact within their organizations and explore how Oracle is helping unlock the full potential of cloud and AI. Join the event to see new capabilities in action and hear from thought leaders and industry movers. Register now at oracle.com/ai-world or follow the news and conversation at oracle.com/news and linkedin.com/company/oracle.

Future Product Disclaimer
The preceding is intended to outline our general product direction. It is intended for information purposes only, and may not be incorporated into any contract. It is not a commitment to deliver any material, code, or functionality, and should not be relied upon in making purchasing decisions. The development, release, timing, and pricing of any features or functionality described for Oracle's products may change and remains at the sole discretion of Oracle Corporation.

Forward-Looking Statements Disclaimer
Statements in this article relating to Oracle's future plans, expectations, beliefs, and intentions are "forward-looking statements" and are subject to material risks and uncertainties. Many factors could affect Oracle's current expectations and actual results, and could cause actual results to differ materially. A discussion of such factors and other risks that affect Oracle's business is contained in Oracle's Securities and Exchange Commission (SEC) filings, including Oracle's most recent reports on Form 10-K and Form 10-Q under the heading "Risk Factors." These filings are available on the SEC's website or on Oracle's website at oracle.com/investor. All information in this article is current as of October 14, 2025 and Oracle undertakes no duty to update any statement in light of new information or future events

Trademarks
Oracle, Java, MySQL and NetSuite are registered trademarks of Oracle Corporation. NetSuite was the first cloud company—ushering in the new era of cloud computing.

SOURCE Oracle

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Unity Bancorp (UNTY - Free Report) came out with quarterly earnings of $1.33 per share, beating the Zacks Consensus Estimate of $1.28 per share. This compares to earnings of $1.07 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +3.91%. A quarter ago, it was expected that this bank holding company would post earnings of $1.17 per share when it actually produced earnings of $1.2, delivering a surprise of +2.56%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Unity Bancorp, which belongs to the Zacks Banks - Northeast industry, posted revenues of $32.82 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 3.20%. This compares to year-ago revenues of $27.66 million. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Unity Bancorp shares have added about 8.1% since the beginning of the year versus the S&P 500's gain of 13.1%.

What's Next for Unity Bancorp?While Unity Bancorp has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Unity Bancorp was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.30 on $32.54 million in revenues for the coming quarter and $4.92 on $126.29 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Banks - Northeast is currently in the top 30% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Norwood Financial Corp. (NWFL - Free Report) , another stock in the same industry, has yet to report results for the quarter ended September 2025. The results are expected to be released on October 22.

This company is expected to post quarterly earnings of $0.68 per share in its upcoming report, which represents a year-over-year change of +41.7%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Norwood Financial Corp.'s revenues are expected to be $21.7 million, up 19% from the year-ago quarter.

Vodafone Group PLC's (LSE:VOD) turnaround story has split the market. Deutsche Bank is doubling down on optimism, while Citi is keeping its hand firmly on the handbrake.

Deutsche’s Robert Grindle has lifted his target price from 135p to 140p and kept his “Buy” rating, pointing to a company that looks “distinctly un-Lemony”, in other words, fewer mishaps and a bit more sunshine.

The shares, last seen at 84.38p, have already risen 27% in sterling terms this year, outpacing European peers.

The German operation, long a drag on sentiment, is now showing signs of life, with organic service revenue growth “back to growth or close to it” in the second quarter.

Emerging markets, especially Africa, are improving in euro terms, and the integration of Three UK is underway. Deutsche sees £700 million of annual cost savings by year five from the merger.

Grindle highlights Vodafone’s “hidden assets”, including stakes in Zegona, Oak Holdings and VodafoneZiggo, that could be monetised to fund further share buybacks.

With the balance sheet strengthening and buyback accretion in play, the dividend could start rising again from 2026, he says.

Citi, by contrast, is not convinced the worst is behind the group. It has kept a 'neutral' rating and raised its price target only slightly, from 75p to 85p, while adding a “90-day negative catalyst watch”. The concern is that too many things remain outside Vodafone’s control.

The bank flags a still-tough German and UK telecoms market, the risk that Deutsche Telekom could accelerate its fibre build, and uncertainty around Germany’s mobile network consolidation.

It also notes a pattern investors know too well: heavy share price falls on the day of interim results in each of the past three years.

Both banks agree the shares look cheap and that synergies from the Three deal should eventually bolster free cash flow. The debate is whether Vodafone can finally stop dropping the call.

Beginning in calendar Q3 2026, Oracle will be the first hyperscaler to offer a publicly available AI supercluster powered by 50,000 AMD Instinct MI450 Series GPUs

, /PRNewswire/ -- Oracle AI World -- Oracle and AMD (NASDAQ: AMD) today announced a major expansion of their long-standing, multi-generation collaboration to help customers significantly scale their AI capabilities and initiatives. Building on years of co-innovation, Oracle Cloud Infrastructure (OCI) will be a launch partner for the first publicly available AI supercluster powered by AMD Instinct™ MI450 Series GPUs—with an initial deployment of 50,000 GPUs starting in calendar Q3 2026 and expanding in 2027 and beyond.

This announcement builds upon the joint work of Oracle and AMD to deliver AMD Instinct GPU platforms on OCI to end customers, beginning with the launch of AMD Instinct MI300X powered shapes in 2024 and extending to the general availability of OCI Compute with AMD Instinct MI355X GPUs. These will be available in the zettascale OCI Supercluster.

Demand for large-scale AI capacity is accelerating as next-generation AI models outgrow the limits of current AI clusters. To train and run these workloads, customers need flexible, open compute solutions engineered for extreme scale and efficiency. OCI's planned new AI superclusters will be powered by the AMD "Helios" rack design, which includes AMD Instinct MI450 Series GPUs, next- generation AMD EPYC™ CPUs codenamed "Venice," and next-generation AMD Pensando™ advanced networking codenamed "Vulcano." This vertically-optimized, rack-scale architecture is designed to deliver maximum performance, scalability, and energy efficiency for large-scale AI training and inference.

"Our customers are building some of the world's most ambitious AI applications, and that requires robust, scalable, and high-performance infrastructure," said Mahesh Thiagarajan, executive vice president, Oracle Cloud Infrastructure. "By bringing together the latest AMD processor innovations with OCI's secure, flexible platform and advanced networking powered by Oracle Acceleron, customers can push the boundaries with confidence. Through our decade-long collaboration with AMD—from EPYC to AMD Instinct accelerators—we're continuing to deliver the best price-performance, open, secure, and scalable cloud foundation in partnership with AMD to meet customer needs for this next era of AI."

"AMD and Oracle continue to set the pace for AI innovation in the cloud," said Forrest Norrod, executive vice president and general manager, Data Center Solutions Business Group, AMD. "With our AMD Instinct GPUs, EPYC CPUs, and advanced AMD Pensando networking, Oracle customers gain powerful new capabilities for training, fine-tuning, and deploying the next generation of AI. Together, AMD and Oracle are accelerating AI with open, optimized, and secure systems built for massive AI data centers."

AMD Instinct MI450 Series GPUs Coming to OCI
AMD Instinct MI450 Series GPU-powered shapes are designed to deliver high-performance, flexible cloud deployment options and provide extensive open-source support. This provides the ideal foundation for customers running today's most advanced language models, generative AI, and high-performance computing workloads. With AMD Instinct MI450 Series GPUs on OCI, customers will be able to benefit from:

Breakthrough compute and memory: Helps customers achieve faster results, tackle more complex workloads, and reduce the need for model partitioning by increasing memory bandwidth for AI training models. Each AMD Instinct MI450 Series GPU will provide up to 432 GB of HBM4 and 20 TB/s of memory bandwidth, enabling customers to train and infer models that are 50 percent larger than previous generations entirely in-memory.
AMD optimized "Helios" rack design: Enables customers to operate at scale while optimizing performance density, cost, and energy efficiency via dense, liquid-cooled, 72-GPU racks. The AMD "Helios" rack design integrates UALoE scale-up connectivity and Ethernet-based Ultra Ethernet Consortium (UEC)-aligned scale-out networking to minimize latency and maximize throughput across pods and racks.
Powerful head node: Helps customers maximize cluster utilization and streamline large-scale workflows by accelerating job orchestration and data processing on an architecture consisting of next-generation AMD EPYC CPUs, code named "Venice." In addition, these EPYC CPUs will offer confidential computing capabilities and built-in security features to help safeguard sensitive AI workloads end to end.
DPU-accelerated converged networking: Powers line-rate data ingestion to improve performance and enhance security posture for large-scale AI and cloud infrastructure. Built on the fully programmable AMD Pensando DPU technology, the DPU-accelerated converged networking offers the security and performance required for data centers to run the next era of AI training, inferencing, and cloud workloads.
Scale -out networking for AI: Enables customers to leverage ultra-fast distributed training and optimized collective communication with a future-ready open networking fabric. Each GPU can be equipped with up to three 800 Gbps AMD Pensando "Vulcano" AI-NICs, providing customers with lossless, high-speed, and programmable connectivity that supports advanced RoCE and UEC standards.
Innovative UALink and UALoE fabric: Helps customers efficiently expand workloads, reduce memory bottlenecks, and orchestrate large multi-trillion-parameter models. The scalable architecture minimizes hops and latency without routing through CPUs and enables direct, hardware-coherent networking and memory sharing among GPUs within a rack via UALink protocol transported over a UALoE fabric. UALink is an open, high-speed interconnect standard purpose built for AI accelerators and supported by a broad industry ecosystem. As a result, customers gain the flexibility, scalability, and reliability needed to run their most demanding AI workloads on open standards-based infrastructure.
Open-source AMD ROCm™ software stack: Enables rapid innovation, offers freedom of vendor choice, and simplifies the migration of existing AI and HPC workloads by providing customers with an open, flexible programming environment, including popular frameworks, libraries, compilers, and runtimes.
Advanced partitioning and virtualization: Enables customers to safely share clusters and allocate GPUs based on workload needs by facilitating the secure and efficient use of resources via fine-grained GPU and pod partitioning, SR-IOV virtualization, and robust multi-tenancy.

To give customers that build, train, and inference AI at scale more choice, OCI also announced the general availability of OCI Compute with AMD Instinct MI355X GPUs. These will be available in the zettascale OCI Supercluster that can scale to 131,072 GPUs. AMD Instinct MI355X-powered shapes are designed with superior value, cloud flexibility, and open-source compatibility. Learn more here and here.

Additional Resources

Learn more about Oracle Cloud Infrastructure
Learn more about OCI Compute 

About Oracle
Oracle offers integrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud. For more information about Oracle (NYSE: ORCL), please visit us at www.oracle.com.

About Oracle AI World
Oracle AI World is where customers and partners discover the latest product and technology innovations, see how AI is being applied across industries, and connect with experts and peers. Attendees will gain practical tips and insights to drive immediate impact within their organizations and explore how Oracle is helping unlock the full potential of cloud and AI. Join the event to see new capabilities in action and hear from thought leaders and industry movers. Register now at oracle.com/ai-world or follow the news and conversation at oracle.com/news and linkedin.com/company/oracle.

About AMD
For more than 55 years AMD has driven innovation in high-performance computing, graphics and visualization technologies. Billions of people, leading Fortune 500 businesses and cutting-edge scientific research institutions around the world rely on AMD technology daily to improve how they live, work and play. AMD employees are focused on building leadership high-performance and adaptive products that push the boundaries of what is possible. For more information about how AMD is enabling today and inspiring tomorrow, visit the AMD (NASDAQ: AMD) website, blog, LinkedIn, Facebook and X pages.

Future Product Disclaimer
The preceding is intended to outline our general product direction. It is intended for information purposes only, and may not be incorporated into any contract. It is not a commitment to deliver any material, code, or functionality, and should not be relied upon in making purchasing decisions. The development, release, timing, and pricing of any features or functionality described for Oracle's products may change and remains at the sole discretion of Oracle Corporation.

Forward-Looking Statements Disclaimer
Statements in this press release relating to Oracle's and AMD's future plans, expectations, beliefs, and intentions are "forward-looking statements" and are subject to material risks and uncertainties. Many factors could affect Oracle's and AMD's current expectations and actual results, and could cause actual results to differ materially. A discussion of such factors and other risks that affect Oracle's and AMD's business is contained in Oracle's and AMD's Securities and Exchange Commission (SEC) filings, including Oracle's and AMD's most recent reports on Form 10-K and Form 10-Q under the heading "Risk Factors." These filings are available on the SEC's website or on Oracle's website at http://www.oracle.com/investor and AMD's website at https://ir.amd.com. All information in this article is current as of October 14, 2025 and Oracle and AMD undertakes no duty to update any statement in light of new information or future events.

Trademarks
Oracle, Java, MySQL and NetSuite are registered trademarks of Oracle Corporation. NetSuite was the first cloud company—ushering in the new era of cloud computing.

SOURCE Oracle

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

ATYR Investors with Losses Encouraged to Contact Hagens Berman

, /PRNewswire/ -- A federal class-action lawsuit has been filed against aTyr Pharma, Inc. (NASDAQ: ATYR) following a devastating 83% drop in the biotech company's stock price after its lead drug candidate failed to meet its primary endpoint in a critical Phase 3 trial.

Prominent shareholders rights firm Hagens Berman has been investigating the alleged claims.

Blog: www.hbsslaw.com/blog

The firm urges investors in aTyr who suffered significant losses to submit your losses now. The firm also encourages persons with knowledge who may be able to assist in the investigation to contact its attorneys.

Class Period: Jan. 16, 2025 – Sep. 12, 2025
Lead Plaintiff Deadline: Dec. 8, 2025
Visit:www.hbsslaw.com/investor-fraud/atyr
Contact the Firm Now: [email protected]
844-916-0895

aTyr Pharma, Inc. (AYTR) Securities Litigation:

The suit, Munguia v. aTyr Pharma Inc., filed in the U.S. District Court for the Southern District of California, alleges that aTyr and its top executives made false and misleading statements about the efficacy of its drug, Efzofitimod, leading investors to purchase stock at artificially inflated prices.

The proposed class covers all investors who acquired aTyr common stock between January 16, 2025, and September 12, 2025, inclusive.

At the heart of the allegations is aTyr's Phase 3, randomized, double-blind, placebo-controlled study, known as EFZO-FIT, which evaluated intravenous Efzofitimod in patients with pulmonary sarcoidosis. The drug was intended to help patients reduce their dependency on steroids.

According to the complaint, throughout the Class Period, aTyr executives expressed overwhelmingly positive statements and confidence in the study's design, particularly its forced taper approach intended to gauge the drug's ability to allow patients to completely wean themselves off steroids.

However, the lawsuit claims that concurrently with these optimistic pronouncements, the company was allegedly concealing material adverse facts concerning Efzofitimod's capability to allow a patient to completely taper their steroid usage—a key measure of efficacy.  The lawsuit asserts that aTyr's statements crossed the line into securities law violations by allegedly misrepresenting the drug's true prospects.

The truth, as alleged in the complaint, came to light on Monday, September 15, 2025. Pre-market, aTyr hosted an investor call announcing that the EFZO-FIT study did not meet its primary endpoint: the change from baseline in mean daily oral corticosteroid (OSC) dose at week 48.

The disappointing topline results prompted a swift and brutal market reaction. aTyr's common stock, which had closed at $6.03 per share on the preceding Friday, September 12, cratered to close at just $1.02 per share on September 15—a catastrophic one-day decline of 83.2%.

In its post-announcement comments, the company stated that it would engage with the Food and Drug Administration (FDA) to determine a path forward, acknowledging the setback.

Hagens Berman's Investigation

Hagens Berman is investigating whether aTyr may have misled investors about its data and trial design while emphasizing Efzofitimod's multi-billion-dollar market opportunity.  "We're scrutinizing whether aTyr's previous representations about the drug's efficacy were materially misleading to investors," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation.

If you invested in aTyr and have substantial losses, or have knowledge that may assist the firm's investigation, submit your losses now »

If you'd like more information and answers to frequently asked questions about the aTyr case and our investigation, read more »

Whistleblowers: Persons with non-public information regarding aTyr should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

SOURCE Hagens Berman Sobol Shapiro LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Prestigious European Society for Medical Oncology Conference “trials-in-progress” session

Pivotal OVATION 3 trial of its DNA-mediated immunotherapy in newly diagnosed patients underway

Company on track with established plans to accelerate patient recruitment

LAWRENCEVILLE, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that a trials-in-progress abstract on the ongoing Phase 3 OVATION 3 clinical trial of IMNN-001, its investigational therapy for the treatment of women with newly diagnosed advanced ovarian cancer, was accepted for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2025, being held October 17-21, 2025 in Berlin, Germany.

IMNN-001, based on IMUNON’s proprietary TheraPlas® technology platform, is an interleukin-12 (IL-12) DNA plasmid vector incorporated in a nanoparticle delivery system, enabling cell transfection followed by persistent, local production and secretion of the IL-12 protein in the tumor microenvironment. IL-12 is a powerful pluripotent cytokine known for inducing strong anti-cancer immunity by promoting T-lymphocyte and natural killer cell proliferation while inhibiting tumor-mediated immune suppression. IMNN-001 is the first therapy to achieve a clinically effective response in advanced (stage IIIC/IV) ovarian cancer including benefits in both progression-free survival and overall survival in a first-line treatment setting when used with standard of care chemotherapy.

In July 2025, the Company announced treatment of the first patient in the pivotal Phase 3 OVATION 3 Study and is working with trial investigators to expand clinical sites and accelerate enrollment. Four sites have been activated to date and are open for patient enrollment, with up to 46 additional sites being considered for activation.

Details of the ESMO virtual poster presentation are as follows:

Abstract Title: OVATION-3: A randomized phase III trial evaluating the safety and efficacy of intraperitoneal IL-12 gene therapy administered in combination with standard neoadjuvant and adjuvant chemotherapy (N/ACT) in newly-diagnosed patients with advanced epithelial ovarian cancer (EOC)

Presenting Author: Premal H. Thaker, M.D., Chief of Gynecologic Oncology, David & Lynn Mutch Distinguished Professor of Obstetrics & Gynecology, Director of Gynecologic Oncology Clinical Research at Washington University School of Medicine, Study Chair of OVATION 2 and Phase 3 OVATION 3 trials

Poster Number: 1234eTiP

Following the conference, the poster presentation will be available on the “Scientific Presentations” page of the IMUNON website at https://investors.imunon.com/scientific-presentations.

About the OVATION 3 Study

OVATION 3 is IMUNON’s pivotal Phase 3 study of IMMN-001, an IL-12 gene-mediated immunotherapy, in women with advanced stage epithelial ovarian cancer. The study is supported with unprecedented overall survival (OS) data from a large, 112-patient, randomized Phase 2 OVATION 2 study showing the following:

Median 13-month increase in OS (HR 0.70) and median 3-month increase in PFS (HR 0.79) in IMNN-001 treatment arm compared to standard of care alone.Better therapeutic effect observed with IMNN-001 treatment compared to the control arm (p=0.0375), as shown by mean 6.5-month extension of time free of progression or death (PFS + OS) captured in totality of treatment effect.Use of poly ADP-ribose polymerase (PARP) inhibitors as part of maintenance therapy further enhanced outcomes, with median OS not yet reached in the IMNN-001 treatment arm as patients surpass 5 years since randomization in the trial compared to median OS of 37 months on standard of care (HR 0.42). The results from the OVATION 2 Study have resulted in invitations to present data from the Phase 2 Study at both the ASCO and ESMO annual meetings and in the peer-reviewed journal Gynecologic Oncology.

The OVATION-3 trial is a robustly designed clinical study with at least 95% statistical power on the primary endpoint of overall survival. The trial design includes two planned interim analyses of the primary endpoint, designed to allow for an accelerated timeline for FDA submission of an IMNN-001 BLA if the primary endpoint reaches statistical significance. OVATION 3 is currently enrolling patients at four clinical sites with up to 46 additional sites being considered for activation.

About the Phase 2 OVATION 2 Study

OVATION 2 evaluated the dosing, safety, efficacy and biological activity of intraperitoneal administration of IMNN-001 in combination with neoadjuvant and adjuvant chemotherapy (N/ACT) of paclitaxel and carboplatin in patients newly diagnosed with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. Treatment in the neoadjuvant period is designed to shrink the tumors as much as possible for optimal surgical removal after three cycles of chemotherapy. Following N/ACT, patients undergo interval debulking surgery, followed by three additional cycles of adjuvant chemotherapy to treat any residual tumor. This open-label study enrolled 112 patients who were randomized 1:1 and evaluated for safety and efficacy to compare N/ACT plus IMNN-001 versus standard-of-care N/ACT. In accordance with the study protocol, patients randomized to the IMNN-001 treatment arm could receive up to 17 weekly doses of 100 mg/m2 in addition to N/ACT. As a Phase 2 study, OVATION 2 was not powered for statistical significance. Additional endpoints included objective response rate, chemotherapy response score and surgical response score.

About IMNN-001 Immunotherapy

Designed using IMUNON's proprietary TheraPlas® platform technology, IMNN-001 is an IL-12 DNA plasmid vector encased in a nanoparticle delivery system that enables cell transfection followed by persistent, local secretion of the IL-12 protein. IL-12 is one of the most active cytokines for the induction of potent anticancer immunity acting through the induction of T-lymphocyte and natural killer cell proliferation. IMUNON previously reported positive safety and encouraging Phase 1 results with IMNN-001 administered as monotherapy or as combination therapy in patients with advanced peritoneally metastasized primary or recurrent ovarian cancer and completed a Phase 1b dose-escalation trial (the OVATION 1 Study) of IMNN-001 in combination with carboplatin and paclitaxel neoadjuvantly in patients with newly diagnosed ovarian cancer. IMUNON previously reported positive results from the recently completed Phase 2 OVATION 2 Study, which assessed IMNN-001 (100 mg/m2 administered intraperitoneally weekly) plus neoadjuvant and adjuvant chemotherapy (N/ACT) of paclitaxel and carboplatin compared to standard-of-care N/ACT alone in 112 patients with newly diagnosed advanced ovarian cancer.

About Epithelial Ovarian Cancer

Epithelial ovarian cancer is the sixth deadliest malignancy among women in the U.S. There are approximately 20,000 new cases of ovarian cancer every year and approximately 70% are diagnosed in advanced stage III/IV. Epithelial ovarian cancer is characterized by dissemination of tumors in the peritoneal cavity with a high risk of recurrence (75%, stage III/IV) after surgery and chemotherapy. Since the five-year survival rates of patients with stage III/IV disease at diagnosis are poor (41% and 20%, respectively), there remains a need for a therapy that not only reduces the recurrence rate but also improves overall survival. The peritoneal cavity of advanced ovarian cancer patients contains the primary tumor environment and is an attractive target for a regional approach to immune modulation.

About IMUNON

IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the gene delivery of viral antigens that can elicit a strong immunological response.

The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed multiple clinical trials including one Phase 2 clinical trial (OVATION 2) and is currently conducting a Phase 3 clinical trial (OVATION 3). IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101). The Company will continue to leverage these modalities and to advance, either directly or through partnership, the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information, please visit www.imunon.com.

Forward-Looking Statements

IMUNON wishes to inform readers that forward-looking statements in this news release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, but not limited to, statements regarding the timing of enrollment of the Company’s clinical trials, the potential of any therapies developed by the Company to fulfill unmet medical needs, the market potential for the Company’s products, if approved, the potential efficacy and safety profile of our product candidates, and the Company’s plans and expectations with respect to its development programs more generally, are forward-looking statements. We generally identify forward-looking statements by using words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, uncertainties relating to unforeseen changes in the course of research and development activities and in clinical trials, including the fact that interim results are not necessarily indicative of final results; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure in conducting clinical trials; the need for IMUNON to evaluate its future development plans; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in IMUNON’s filings with the Securities and Exchange Commission. IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Contacts:  Media Investors Jenna UrbanPeter VozzoCG lifeICR [email protected]@icrhealthcare.com

  

Montréal – TheNewswire - le 14 octobre 2025 – La Corporation Éco-Minière St-Georges (CSE: SX) (OTCQB: SXOOF) (FSE: 85G1) et sa filiale en propriété exclusive, Métallurgie St-Georges, annoncent une mise à jour concernant leur usine pilote de production de lithium ainsi que d’autres initiatives métallurgiques.

Au cours des derniers mois, la Corporation et ses partenaires ont soigneusement évalué plusieurs fournisseurs potentiels de spodumène à travers le Canada. Plusieurs candidats ont manifesté leur intérêt à fournir du concentré. Le consortium de partenaires — Coalia, LiOH Corp. et Métallurgie St-Georges (SXM) — a maintenant reçu un premier envoi d’environ cinq tonnes de concentré de spodumène d’origine canadienne. Les travaux initiaux et les essais sont en cours, et le matériel reçu a déjà été traité à l’étape de transformation alpha-bêta. Des mises à jour régulières sur les résultats du programme seront communiquées lorsqu’elles seront disponibles.

« (…) La technologie au lithium de SX apportera des avancées majeures à la métallurgie du lithium grâce à plusieurs améliorations clés par rapport aux procédés traditionnels. Elle permet d’obtenir une grande pureté et un taux de récupération élevé du lithium, tout en réduisant la quantité de résidus générés, la consommation d’eau, d’acide et de réactifs, et en produisant des sous-produits de valeur tels que l’alumine et des engrais à base d’azote. Ensemble, ces améliorations procurent un fort potentiel économique, permettant au procédé de fonctionner à des coûts inférieurs aux alternatives chinoises. Le projet pilote en cours fournira les données nécessaires à la réalisation d’une étude de faisabilité qui sera lancée d’ici mars 2027, laquelle inclura une analyse détaillée des coûts d’investissement (CAPEX) et d’exploitation (OPEX) afin de confirmer la position de cette technologie comme l’une des solutions les plus durables et économiques de l’industrie (…) », a commenté Mathieu Boudreau, chef de projet chez Coalia.

Autres initiatives métallurgiques

SXM continue de faire progresser deux projets axés sur le nickel, soutenus par des demandes de subvention soumises en collaboration avec plusieurs partenaires, dont un fournisseur de procédés métallurgiques de premier rang. Parmi les principaux contributeurs à ces initiatives figurent Coalia et l’entreprise montréalaise IGS.

Parallèlement, des préparatifs sont en cours pour l’extraction complète de minéraux de valeur grâce au traitement métallurgique d’échantillons en vrac préalablement recueillis sur les projets de minéraux critiques Julie et Manicouagan. Ces travaux devraient débuter avant la fin de l’année.

De plus, par l’entremise de sa filiale en propriété exclusive Iceland Resources ehf, la Corporation collabore avec un producteur d’énergie géothermique en Islande. Les premiers essais sur le matériel fourni ont révélé des teneurs variant d’environ ~67 g/t Au-équivalent. à ~437 g/t Au-équivalent., soit plus de 14 onces d’or équivalent par tonne. Plus de 200 kilogrammes de ce matériel ont été importés avec succès au Canada pour des tests d’extraction et de séparation, lesquels alimenteront les initiatives en cours visant à établir une opération régulière.

Pour plus d’informations sur les résultats précédents, veuillez consulter le communiqué suivant :

https://webfiles.thecse.com/SX_Communique_-_24_avril_2023_-_St-Georges_recoit_dimpressionants_resultats_preleves_in_situ_dans_une_installation_geothermique_en_Islande.pdf?q1qdc3OHZoSMmiaNm6vVzqo.K2ajuBwT

Prolongation de la validité de bons de souscription

La Corporation annonce également la prolongation de la durée de certains bons de souscription, dont les dates d’expiration initiales étaient prévues en novembre et décembre 2025 :

Bons émis le 1er novembre 2022 (2 850 000) :

Modalités initiales: Prix d’exercice de 0,29 $ pour une période de 36 mois suivant la date de clôture. 

Nouvelles modalités: Prix d’exercice de 0,29 $ pour une période de 60 mois suivant la date de clôture. Nouvelle date d’expiration : 1er novembre 2027. 

Bons émis le 18 novembre 2022 (3 600 000) :

Modalités initiales: Prix d’exercice de 0,29 $ pour une période de 36 mois suivant la date de clôture. 

Nouvelles modalités: Prix d’exercice de 0,29 $ pour une période de 60 mois suivant la date de clôture. Nouvelle date d’expiration : 18 novembre 2027. 

Bons émis le 30 décembre 2022 (5 000 000) :

Modalités initiales: Prix d’exercice de 0,50 $ pour une période de 36 mois suivant la date de clôture. 

Nouvelles modalités: Prix d’exercice de 0,50 $ pour une période de 60 mois suivant la date de clôture. Nouvelle date d’expiration : 30 décembre 2027. 

Bons émis le 23 novembre 2023 (14 259 260) :

Modalités initiales: Prix d’exercice de 0,175 $ pour une période de 24 mois suivant la date de clôture. 

Nouvelles modalités: Prix d’exercice de 0,175 $ pour une période de 60 mois suivant la date de clôture. Nouvelle date d’expiration : 23 novembre 2028. 

Bons émis le 20 décembre 2023 (7 703 700) :

Modalités initiales: Prix d’exercice de 0,175 $ pour une période de 24 mois suivant la date de clôture. 

Nouvelles modalités: Prix d’exercice de 0,175 $ pour une période de 60 mois suivant la date de clôture. Nouvelle date d’expiration : 20 décembre 2028. 

AU NOM DU CONSEIL D'ADMINISTRATION

Neha Edah Tally

Secrétaire corporative

À propos du partenariat de l’usine pilote de lithium

L’usine pilote de lithium est conçue pour produire du nitrate de lithium et potentiellement de l’hydroxyde de lithium, ainsi que divers sous-produits générés par la technologie de traitement exclusive de St-Georges. L’installation est exploitée dans les locaux de Coalia, un centre de recherche de premier plan basé au Québec.

En vertu de l’entente actuelle, LiOH Corp., en contribuant financièrement à l’initiative, détient en contrepartie un droit d’exclusivité limité de cinq ans sur la technologie, lui permettant de collaborer aux essais et de partager l’ensemble des données générées durant les opérations pilotes.

Toute la propriété intellectuelle et les données résultantes demeurent la propriété de Métallurgie St-Georges (SXM) et peuvent être utilisées par la Corporation et ses filiales pour construire leurs propres installations commerciales. Toutefois, aucune autre licence ne sera accordée à des tiers tant que la phase pilote sera active.

Une étude de faisabilité, s’appuyant sur les résultats du projet pilote, devrait être amorcée avant le 31 mars 2027. À son achèvement, LiOH Corp. aura la possibilité de prolonger son exclusivité limitée pour une période supplémentaire de cinq ans si elle entreprend la construction d’une usine commerciale. Les résultats de cette étude permettront à SXM de concevoir et de construire une installation à l’échelle commerciale, après quoi de nouvelles licences technologiques pourront être envisagées pour d’autres partenaires.

À propos de LiOH Corp.

LiOH Corp. est une société canadienne axée sur le développement et la commercialisation de technologies avancées de raffinage du lithium.

Sa mission est de renforcer la chaîne d’approvisionnement canadienne en lithium par l’innovation et des partenariats stratégiques avec des institutions de recherche et des développeurs miniers de premier plan.

En collaborant avec SXM et Coalia, LiOH vise à accélérer le déploiement de procédés de conversion du lithium durables et à haut rendement, soutenant la croissance des marchés émergents des véhicules électriques et du stockage d’énergie.

À propos de Iceland Resources ehf

Iceland Resources est une filiale en propriété exclusive de St-Georges Eco-Mining Corp.

Axée sur l’or, l’argent et les métaux énergétiques, la société détient la licence du projet Thormodsdalur, situé près de la capitale islandaise Reykjavik, et a conclu des ententes avec les propriétaires du projet aurifère Elbow Creek. Plusieurs autres licences sont actuellement en phase de demande.

Iceland Resources possède également une vaste base de données regroupant des échantillonnages géochimiques, des cartographies géologiques et des programmes détaillés de forage. Ces travaux historiques offrent un potentiel considérable pour une exploitation minière écologique, avec des perspectives additionnelles dans les opérations géothermiques pour la production in situ, le traitement des résidus et les effluents hydrothermaux.

À propos de la Corporation Éco-Minière St-Georges

St-Georges développe de nouvelles technologies et détient un portefeuille diversifié d'actifs et de propriété intellectuelle en instance de brevet au sein de plusieurs filiales très prometteuses, notamment : EVSX, une initiative de premier plan en Amérique du Nord dans le traitement avancés des batteries usagées ; Métallurgie St-Georges, avec de la recherche et développement métallurgique et la propriété intellectuelle connexe, y compris le traitement et la récupération de lithium à haute teneur à partir du spodumène ; Iceland Resources, avec des projets d'exploration à haute teneur en or et en argent, y compris l'actif aurifère phare Thor ; H2SX, qui développe une technologie pour convertir le méthane en carbone solide et en hydrogène turquoise ; et des projets d'exploration au Québec, notamment les projets de minéraux critiques Manicouagan et Julie sur la Côte-Nord du Québec et le projet de niobium Notre-Dame au Lac St-Jean.

Consultez le site Web de la corporation : https://stgeorgesecomining.com/fr/  

Pour toute information supplémentaire ou questions : [email protected]  

La Bourse des valeurs canadiennes (CSE) n'a pas examiné ce communiqué et n'accepte aucune responsabilité quant à la pertinence ou à l'exactitude de son contenu.

  

A smartphone with a displayed Broadcom logo is placed on a computer motherboard in this illustration taken March 6, 2023. REUTERS/Dado Ruvic/Illustration Purchase Licensing Rights, opens new tab

SummaryCompaniesThor Ultra networking chip aims to scale up AI networksChip launch to represent hardening of AI battle with NvidiaBroadcom sees its AI market as a $60 billion to $90 billion opportunity in 2027SAN FRANCISCO, Oct 14 (Reuters) - Broadcom

(AVGO.O), opens new tab is launching a new networking chip on Tuesday that will help companies build artificial intelligence computing systems by stringing together hundreds of thousands of chips that crunch data, deepening its rivalry with Nvidia

(NVDA.O), opens new tab.

The chip, called the Thor Ultra, enables computing infrastructure operators to deploy far more chips than they otherwise could, allowing them to build and run the large models used to power AI apps such as ChatGPT.

Sign up here.

The Thor Ultra will battle Nvidia's networking interface chips and aim to further entrench Broadcom's control of network communications inside data centers designed for AI applications.

It comes after Broadcom on Monday unveiled a deal to roll out 10 gigawatts worth of custom chips for ChatGPT maker OpenAI beginning in the second half of 2026, challenging Nvidia's grip on the AI accelerator market.

AI represents a big opportunity for Broadcom. Chief executive Hock Tan said late last year the market the company is going after for its various AI chips is in the range of $60 billion to $90 billion in 2027, divided between its networking chips and the data center processors it helps Alphabet's

(GOOGL.O), opens new tab Google and OpenAI make.

Broadcom reported AI revenue of $12.2 billion in fiscal 2024. In September, it announced a new, unnamed $10 billion customer for its custom data center AI chips.

The Thor Ultra chip, part of Broadcom's growing catalog of networking chips, operates as a critical link between an AI system and the rest of the data center. The networking chips help data center operators move information around inside a facility.

"In the distributed computing system, network plays an extremely important role in building these large clusters," Ram Velaga, a Broadcom senior vice president, told Reuters. "So I'm not surprised that anybody who's in the GPU business wants to make sure that they are participating in the networking."

FOCUSING ON CHIP DESIGNWhile networking chips are crucial to the company's plans, the AI chips Broadcom helps design for large cloud computing companies such as Google are lucrative.

Broadcom has worked on multiple generations of Google's Tensor processor, which Google began designing more than a decade ago. The Tensor chips have generated billions of dollars in revenue for Broadcom, according to analyst estimates.

During a tour in September of Broadcom's San Jose network chip-testing labs where engineers work on current and forthcoming designs of its networking chips, company executives detailed measures taken to construct and test new networking processors.

Towards that end, Broadcom's engineers doubled the bandwidth on Thor Ultra compared with the prior version. They put the chips through rigorous testing and evaluation from the earliest stages of production.

To make a chip like the Thor Ultra or flagship series of Tomahawk networking switches, the engineers build an entire system around the chip. With the hardware system team, the engineers will discuss what kind of package the chip uses, how much power it will need and how much heat it will emit, Velaga said.

Broadcom does not sell servers itself but offers the designs for components and systems it creates for testing to its customers in order to give them a reference point to construct the networking infrastructure around it.

"For every dollar we invest in our silicon, there is at least $6 to $10 that our ecosystem partners are investing," Velaga said. "So a lot of our focus is on design, as if we are almost ready to take it to production."

Reporting by Max A. Cherney in San Francisco; Editing by Muralikumar Anantharaman

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Max A. Cherney is a correspondent for Reuters based in San Francisco, where he reports on the semiconductor industry and artificial intelligence. He joined Reuters in 2023 and has previously worked for Barron’s magazine and its sister publication, MarketWatch. Cherney graduated from Trent University with a degree in history.

PepsiCo remains a long-term favorite, but current headwinds and macro uncertainty justify maintaining a Hold rating for now. PepsiCo's recent earnings beat estimates, yet declining gross and operating profits signal ongoing challenges in its turnaround strategy. Strategic moves—like acquiring Walmart's CFO, increasing its Celsius stake, and cost-saving initiatives—position PepsiCo for future growth.

CHONGQING, CHINA - AUGUST 08: In this photo illustration, a smartphone displays the logo of Oklo Inc. (NYSE: OKLO), a nuclear energy company developing advanced fission power plants, in front of a screen showing the company's latest stock market chart on August 8, 2025 in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

Getty Images

Oklo Inc. (NYSE: OKLO), the advanced nuclear technology firm developing small modular reactors (SMRs), has emerged as one of the most remarkable stock market narratives of 2025. Shares are currently trading at approximately $168, having increased more than seven times year-to-date, as investors speculate on nuclear's capability to power AI data centers, industrial sites, and the overall transition to clean energy.

However, following such an incredible surge, the pivotal question has evolved: is Oklo valued for perfection — or for potential disappointment? Additionally, see: Oklo Stock To Increase 50% More?

For those looking for an upside with reduced volatility compared to holding an individual stock, consider the High Quality Portfolio. It has significantly outperformed its benchmark, which includes a mix of the S&P 500, Russell, and S&P MidCap indexes, achieving returns that have exceeded 105% since its inception. Collectively, HQ Portfolio stocks have demonstrated better returns with lower risk compared to the benchmark index; delivering a smoother ride, as illustrated in HQ Portfolio performance metrics. Furthermore, see Can PayPal Stock Fall To $50?

The Core Concern: Too Much Future, Too Little PresentOklo continues to be a pre-revenue entity, and while its aspirations are commendable, revenue generation is still quite a few years away. The firm has indicated about 14 GW of customer interest — a pipeline potentially translating to $5 billion or more in yearly revenue by 2028 if projects come to fruition.

Nonetheless, at the current share price of $167, Oklo holds a market capitalization of about $25 billion, despite not having produced or sold a single reactor yet. This valuation is generally associated with established industrial or energy companies that have billions in current revenue, rather than pre-commercial ventures still navigating licensing and prototype phases.

Even if Oklo reaches $5 billion in annual revenue by 2028, the stock is presently trading at nearly five times potential sales for 2028. Should execution falter or timelines extend — which is a plausible scenario in the nuclear industry — a reassessment toward two times sales would suggest a share price closer to $70–75, representing a 50% decline from current prices.

Key Downside RisksRegulatory Delays: Oklo’s reactor design is still pending full approval from the U.S. Nuclear Regulatory Commission (NRC), a process that traditionally takes many years. Any holdup could delay commercialization into the next decade.Capital Requirements: The construction and deployment of SMRs is extremely capital-intensive. Oklo will likely need to secure billions in the coming years — potentially through share dilution — to finance development, construction, and fuel procurement.Execution Hurdles: Transitioning from engineering concepts to large-scale commercial deployment involves significant technical and operational challenges. Cost overruns or supply chain issues could impair early projects.Valuation Stretch: With shares rising over 600% in 2025, Oklo trades well ahead of its fundamentals. Any slowdown in regulatory updates or sector rotation could prompt sharp corrections.The Structural RealityNuclear energy — particularly SMRs — constitutes one of the most complex and sluggish sectors of energy infrastructure. Each phase, from licensing to construction and operation, demands years and billions of dollars. Even with robust customer interest, Oklo’s capacity to transform those commitments into operational reactors remains unproven.

In contrast to software or solar initiatives that can expand rapidly, SMRs necessitate patience, capital, and impeccable execution — three elements that markets seldom reward simultaneously.

The VerdictAt $167 per share, Oklo’s market capitalization reflects substantial expectations — not only for regulatory success but also for perfect execution and swift commercialization. The firm could ultimately validate these expectations if it achieves multi-gigawatt deployment by 2028, but the journey is protracted and uncertain.

If timeframes extend or investor enthusiasm wanes, a retreat toward the $70–80 range would be entirely plausible — and perhaps even beneficial.

Oklo stands as one of the most audacious bets in clean energy today: high potential, high visibility, and equally high risk. For investors with long-term perspectives and a strong tolerance for volatility, it continues to be a captivating narrative. For others, the existing valuation likely presumes too much, too quickly.

Now, we apply a risk assessment framework while constructing the Trefis High Quality (HQ) Portfolio, which, with a collection of 30 stocks, has a record of comfortably outperforming the S&P 500 over the last four-year timeframe —and has achieved returns surpassing 105% since its inception. Why is that? As a collective, HQ Portfolio stocks have yielded better returns with lower risk compared to the benchmark index; offering a steadier experience as demonstrated in HQ Portfolio performance metrics.

CANADA - 2025/09/28: In this photo illustration, the MP Materials logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

SOPA Images/LightRocket via Getty Images

MP Materials (NYSE:MP), an American company specializing in rare-earth materials and based in Las Vegas, Nevada, experienced a stock increase of approximately 8% on Friday after China revealed new export restrictions on rare-earth elements. The updated regulations will necessitate that foreign purchasers secure licenses, heightening concerns over supply shortages. In reaction, President Donald Trump threatened more substantial tariffs on Chinese imports and indicated the possibility of canceling his meeting with President Xi, rekindling U.S.-China trade frictions. This situation could provide a significant advantage for MP Materials. With Washington already investing $400 million in the firm and ensuring future purchases, MP stands to gain from any initiative that encourages the U.S. to reduce reliance on Chinese supplies. Investors are currently wagering on increased demand, improved pricing, and ongoing policy support for U.S.-based manufacturers.

MP stock has recently made substantial gains, yet we presently find it unappealing. This could be seen as a warning, and there exists considerable risk in depending on a single stock. Nonetheless, there is immense value to the broader diversified strategy we adopt with Trefis High Quality Portfolio. Additionally, contemplate what the long-term performance of your portfolio could resemble if you integrated 10% commodities, 10% gold, and 2% crypto along with equities.

Geopolitical changes have only heightened the significance of this role. Earlier this year, after Washington enacted higher tariffs on Chinese goods, Beijing implemented export controls on rare earths. China's rare earth exports have been severely impacted: in September 2025, exports fell by 31% from August to reach 4,000.3 tonnes, marking the lowest monthly figure since February 2025. Now, China has broadened its rare earth export restrictions to encompass 12 of the 17 rare earth elements, with new regulations set to take effect from December 1. These regulations will mandate licenses for the export of rare earth magnets and related products, including those for foreign companies that utilize Chinese-origin rare earth materials or technologies. These events underscore the necessity for a secure domestic supply.

This positions MP Materials as one of the most strategic companies in America's endeavor to establish its critical minerals supply chain. The firm owns and operates the Mountain Pass Mine in California – currently the only operational rare-earth mine and processing facility in the United States. Its primary focus is on producing Neodymium-Praseodymium (NdPr), critical for high-strength permanent magnets used in EV motors, wind turbines, drones, and defense apparatus. In July, the U.S. Department of Defense became MP’s largest shareholder following a $400 million equity investment aimed at boosting the company’s magnet production capacity. MP also entered into a $500 million supply agreement with Apple, using prepayments to finance much of its new Independence facility in Texas, which will manufacture finished rare-earth magnets.

Operational AdvancementsMP’s operational advancements have been robust. In Q2 2025, the company announced record NdPr oxide production, up 119% year-on-year, with sales volumes tripling to 443 metric tons. Revenue soared 84% to $57.4 million, surpassing expectations. Management anticipates another sequential production increase of 10%–20% in Q3. The company is also progressing downstream — shifting from raw oxide production to high-value magnet alloys and finished magnets, a segment where sales have already reached $20 million last quarter. MP aims to scale this to 10,000 metric tons annually by 2028, which could significantly enhance margins. Financially, MP remains well-capitalized, holding nearly $2 billion in cash, which provides it with the flexibility for expansion and R&D.

What Are The Risks?Despite its strong fundamentals and policy backing, valuation is a significant concern. MP trades at approximately 50x forward revenue, comparing more closely with high-growth tech companies than with miners. The business is still unprofitable, reporting a $53.5 million net loss and consuming $126 million in cash year-to-date. Although geopolitical tailwinds have driven its rise — the stock has increased over 500% year-to-date — this reliance could work against it. Any easing in trade tensions or normalization in Chinese exports might weaken the bullish perspective. With China producing 90% of the world’s rare-earth magnets, MP’s advantage remains particularly sensitive to policy changes.

The Trefis High Quality (HQ) Portfolio, comprising a selection of 30 stocks, has a proven history of comfortably surpassing its benchmark that encompasses all three – S&P 500, Russell, and S&P midcap – achieving returns in excess of 105% since its inception. Why is this the case? Collectively, HQ Portfolio stocks have delivered superior returns with lower risk compared to the benchmark index, resulting in a less volatile experience, as evident in HQ Portfolio performance metrics.

Wells Fargo said its profit increased 9% in the third quarter.

Automaker cites end of government-funded subsidies and regulatory mandates that fueled electric-vehicle growth.

Intuitive Surgical Today

ISRG

Intuitive Surgical

$435.73 +6.14 (+1.43%)

As of 10/13/2025 04:00 PM Eastern

52-Week Range$425.00▼

$616.00P/E Ratio60.77

Price Target$584.76

Intuitive Surgical Inc. NASDAQ: ISRG is entering a potential breakout window as it heads into its next earnings report on October 21, 2025. A wave of recent developments has improved the outlook and set the stage for a possible rally leading into—or following—the announcement.

With new FDA approvals and a green light for European expansion, Intuitive Surgical now has access to a much larger, more actionable customer base. These developments have meaningfully expanded its addressable market and could drive increased adoption of its systems across both the United States and abroad.

Get Intuitive Surgical alerts:

That broader reach should begin to show up in improved earnings results over the coming quarters. As is often the case in the healthcare sector, regulatory developments play a pivotal role in shaping investor sentiment.

Notably, there’s growing speculation that key regulations could soon clear, especially given recent buying activity from several U.S. Congress members—a signal that hasn't gone unnoticed by the market. As a result, investors are now assigning a premium valuation to the company, reflecting heightened expectations for future growth. For retail investors, this is an opportunity worth serious consideration.

Why Intuitive Surgical Can Win
Intuitive Surgical develops artificial intelligence-driven robotics for surgical procedures, enabling medical professionals to perform these procedures remotely with precision and accuracy. Given the nature of this company's industry, it is inherently surrounded by moats that neither competition nor the adoption of artificial intelligence can breach.

That could be why markets view this as the premium company, but there is much more behind it. One of these drivers is the recent FDA approval for Intuitive Surgical’s da Vinci 5 software features, which will facilitate further adoption of this technology and enable remote surgical procedures aided by robotics and artificial intelligence.

Secondly, the Ion endoluminal system trials have now been cleared across Europe and the United States, involving over 2,000 subjects. These studies increase the likelihood that this company will begin to report more diversified and rapidly growing revenue streams, enhancing its valuation.

Despite these bullish factors, the stock trades at only 70% of its 52-week high (well into bear market territory), creating a more attractive risk-to-reward ratio for new and existing shareholders. Some of these new shareholders include congressional members who may or may not possess valuable information regarding future FDA approvals and developments.

Markwayne Mullin bought up to $100,000 at an average price of $443.99 per share, or Ro Khanna, who bought up to $15,000 at an average of $466.66. These purchases were made in September 2025, just a month before the company releases its quarterly results, likely to include some positive guidance given the recent FDA approvals and European expansion.

What Markets Think of Intuitive Surgical Stock
Intuitive Surgical Stock Forecast Today12-Month Stock Price Forecast:
$584.76
34.20% Upside

Moderate Buy
Based on 22 Analyst Ratings

Current Price$435.73High Forecast$700.00Average Forecast$584.76Low Forecast$440.00Intuitive Surgical Stock Forecast Details

The most clear-cut way investors can gauge sentiment is through valuation multiples. In the case of Intuitive Surgical, a price-to-earnings ratio of 59.9x indicates a significant preference for this stock. This multiple commands a steep premium for the medical instruments industry, at only 26.3x, and there must be a reason why markets are willing to overpay here.

The Wall Street analyst consensus price target on the stock is $589.43 per share, which implies a 37.2% upside potential from its current trading price, not accounting for the potential financial benefits that could arise from recent developments.

Despite these tailwinds, the company reported net earnings per share (EPS) of $2.19 in its latest quarterly results, 13% above the MarketBeat consensus of $1.93. This trade can work for many fundamental reasons, but it also goes beyond Intuitive Surgical’s business.

The Healthcare Select Sector SPDR Fund NYSEARCA: XLV has underperformed the broader S&P 500 index by approximately 22% over the past 12 months, marking the widest spread in over a decade. This means that healthcare stocks, overall, are compressed in terms of valuations and price action.

Should a recovery extend to the entire sector, Intuitive Surgical can amplify its bullish fundamentals and accelerate its rally higher alongside its other peers in the space, thereby creating a fantastic risk-to-reward setup.

Should You Invest $1,000 in Intuitive Surgical Right Now?Before you consider Intuitive Surgical, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intuitive Surgical wasn't on the list.

While Intuitive Surgical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

- Reports Sixth Consecutive Quarter of Revenue over $5 million Highlighted by 150% Annual Increase in Medical Market Sales-

-Fiscal First Half Net Income Increases 35%-

-Backlog Increased 50% Sequentially Reflecting New Order Momentum-

-Updates FY26 Guidance Reflecting Improved Outlook, Anticipating Modest Revenue Growth with Increasing Demand in the Medical Device Market-

-Conference Call Today at 10:30 am ET-

MILTON, N.Y., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Sono-Tek Corporation (Nasdaq: SOTK), the leading developer and manufacturer of ultrasonic coating systems, today reported financial results for the second quarter and first half of fiscal year 2026, ended August 31, 2025.

Second Quarter Fiscal 2026 Highlights

Net Sales for the quarter increased to $5.163 million compared to $5.162 million year over year and increased sequentially compared to $5.13 million in the first quarter of fiscal 2026.Gross profit for the quarter increased 3% year over year to $2.6 million compared with $2.5 million.Net income for the quarter increased 24% to $424 thousand, or $0.03 per share, compared with $341 thousand, or $0.02 per share. First Half Fiscal 2026 Highlights

Record first half fiscal 2026 revenue increased year over year to $10.30 million compared to $10.19 million.Gross profit increased 6% year over year to $5.3 million compared with $5.0 million, primarily due to product mix and favorable warranty expenses in the current period.Net income increased 35% year over year to $909 thousand, or $0.06 per share, compared with $672 thousand, or $0.04 per share. Balance Sheet, Backlog and Guidance for Fiscal Year 2026

As of August 31, 2025, cash, cash equivalents and marketable securities totaled $10.6 million with no outstanding debt.Total equipment and service-related backlog remains strong at $11.21 million compared to $11.6 million at the end of Q2 FY2025 and increased 50% compared to $7.48 million at the end of Q1 FY2026, reflecting new order momentum from the medical market. For the full fiscal year, the Company is updating its guidance reflecting an improved outlook anticipating modest revenue growth, balancing a cautious view as the market adjusts to recent shifts in governmental clean energy and tariff policies with a positive offset from growing demand in the medical device market. Dr. Christopher L. Coccio, Executive Chairman, stated, “We are pleased to report continued growth and profitability in line with our guidance with the continuing trend of over $5 million in quarterly revenue for the past six quarters. Importantly, we remain solidly profitable with strong margins and effective cost controls. Based on projected shipments for the second half of our fiscal year 2026, we are raising guidance slightly, now anticipating modest revenue growth, taking into consideration evolving governmental clean energy incentives and tariff policies which each may affect the initiation and timing of customer orders. Despite the evolving landscape in the clean energy industry, we have successfully offset it with our diversification strategy into other sectors such as the medical device industry. It is gratifying to see the promising demand in the medical device industry that we projected coming to fruition with our recently announced $5 million dollar order for multiple state-of-the-art MediCoat systems designed for high-precision, scalable manufacturing in addition to our most recent order of over $2.8 million from another major medical device manufacturer. With a healthy balance sheet, solid backlog and strong customer demand, we remain laser focused on execution and look forward to building on our recent success.”

Steve Harshbarger, CEO & President of Sono-Tek stated, “We continue to see the success of our growth strategies with customers moving into complex large-scale production systems with significantly higher average selling prices “ASPs”. Customer demand and momentum remain strong, and it is validating to see the growing adoption of Sono-Tek’s advanced coating platforms by leading medical device manufacturers worldwide. We are well positioned with our strong balance sheet and backlog to navigate potential short-term demand shifts that may result from changes in tariff policies and clean energy incentives. We remain focused on our long-term growth strategy and look forward to continued revenue growth and profitability over the long term.”

Second Quarter Fiscal 2026 Results

(Narrative compares with prior-year period unless otherwise noted) ($ in thousands)

 Three Months Ended August 31,
 Change
  2025
  2024
 $
 %
Net Sales$5,163  $5,162  1  0% Gross Profit$2,590  $2,516  74  3% Gross Margin 50%
   49%
                   Operating Income$421  $286  135  47% Operating Margin 8%
   6%
                   Net Income$424  $341  83  24% Net Margin 8%
   7%
          Net Sales: $5.163 million, a slight increase from the $5.162 million in the second quarter of fiscal year 2025. This marks the sixth consecutive quarter with sales over $5 million.

Gross Profit: $2.6 million, up 3% from the prior year second quarter of $2.5 million. Gross margin increased to 50% from 49%, mainly due to a favorable product mix of high ASP systems, reflecting further maturation of our product offerings, with reduced costs and favorable warranty expenses in the current period.Operating Income: Increased 47% to $421 thousand compared to $286 thousand in the second quarter of fiscal year 2025, due to an increase in gross profit combined with lower operating expenses.Net Income: Increased 24% to $424 thousand, up from $341 thousand in the second quarter of fiscal year 2025, reflecting a combination of higher gross profit and lower operating expenses.Other Income: Interest and dividend income decreased slightly to $82 thousand for the second quarter of fiscal year 2026 from $85 thousand in the second quarter of fiscal year 2025. Second Quarter Fiscal Year 2026 Product and Market Sales Overview

Product Categories: In-Line Coating Systems (previously referred to as Integrated Coating Systems) sales decreased by $493 thousand, or 24%, to $1.53 million, primarily driven by a customer-requested delivery delay in the clean energy sector. Multi-Axis Coating Systems increased by $99 thousand, or 5%, to $2.03 million. Fluxing sales increased by $46 thousand or 39% to $165 thousand, reflecting increased demand from Asia. OEM sales increased by $189 thousand, or 92%, to $394 thousand driven by strong fluxer OEMs and two new OEM’s. Spare parts, Services and Other sales increased by $160 thousand, or 18% to $1.04 million. During the current reporting period, the Company updated the title of its product category previously referred to as “Integrated Coating Systems” to “In-Line Coating Systems.” We made this change to provide greater clarity in describing this segment of our business. The definition and contents of this category remain unchanged.In-Line Coating Systems include Sono-Tek products that are typically stationary platforms with minimal motion control and may occasionally incorporate a simple axis of movement such as a rotation fixture. These systems are commonly installed over moving substrates such as conveyors or webs, which may be provided either by Sono-Tek or by the customer. They often employ multiple ultrasonic nozzles to provide uniform coverage over larger areas in continuous production environments. In-Line Coating Systems are unlike our Multi-Axis Coating Systems, which commonly utilize XYZ motion platforms or 6+ axis robotic configurations. End Markets: The Medical market increased by 150% y-o-y or $602 thousand to $1.00 million, led by balloon coating systems shipped to the U.S., Europe, and China. Alternative/Clean Energy decreased slightly by 3% y-o-y or $65 thousand, to $2.43 million, supported by a strong clean energy backlog going into FY 2026. The Electronics market declined slightly by 1% y-o-y, down $22 thousand to $1.46 million. The Industrial market declined 68% or $517 thousand to $238 thousand, influenced by a large FY 2025 European glass coating order that did not repeat.
Geography: US/Canada sales decreased 22% y-o-y, or $775 thousand, driven by slowing momentum in the US clean energy industry. Offsetting the US sales decline, sales in Asia increased 153% y-o-y, or $562 thousand, with major growth in China and other parts of Asia. EMEA sales increased 25%, or $288 thousand while Latin American sales were down $74 thousand. First Half Fiscal Year 2026 Overview
(Narrative compares with prior-year period unless otherwise noted) ($ in thousands)

 Six Months Ended August 31, Change  2025   2024  $
 %Net Sales$10,295  $10,193  102  1% Gross Profit$5,254  $4,971  283  6% Gross Margin 51%   49%               Operating Income$905  $524  381  73% Operating Margin 9%   5%               Net Income$909  $672  237  35% Net Margin 9%   7%        Net Sales: $10.30 million, an increase from $10.19 million in the first half of fiscal year 2025.Gross Profit: $5.3 million, up 6% from the first half of fiscal year 2025 of $5 million. Gross margin increased to 51% from 49%, mainly primarily due to product mix and favorable warranty expenses in the current period.Operating Income: Increased 73% to $905 thousand compared to $524 thousand in the first half of fiscal year 2025, due to an increase in gross profit combined with lower operating expenses.Net Income: Increased 35% to $909 thousand, up from $672 thousand in the first half of fiscal year 2025, reflecting a combination of higher gross profit and lower operating expenses.Other Income: Interest and dividend income decreased slightly to $224 thousand for the first half of fiscal year 2026 compared to $228 thousand for the first half of fiscal year 2025. First Half Fiscal Year 2026 Product and Market Sales Overview

Product Categories: In-Line Coating Systems (previously referred to as Integrated Coating Systems) sales increased by $1.82 million, or 65%, to $4.58 million, driven by shipments of six high-ASP systems to a major solar customer totaling $4.42 million. Fluxing sales increased by $64 thousand or 25% driven by strength in Asia. Multi-Axis Coating Systems declined $1.89 million, or 41%, to $2.71 million following a strong FY2025 for semiconductor systems that did not repeat, and slower clean energy activity in FY2026. OEM sales were down slightly by $13 thousand or 2% and Spare Parts, Services and Other sales were up $126 thousand, a 6% increase.
End Markets: The Medical market rose by 44% or $553 thousand, supported by strong balloon coating systems shipped to the U.S., Europe, and China, and increased stent coating activity in Europe. Alternative/Clean Energy rose 19% y-o-y, up $901 thousand, driven by the shipment of six high ASP solar coating systems. The Electronics market declined 21% y-o-y, down $646 thousand following strong FY2025 semiconductor sales, and FY2026 customer timing for similar machines. The Industrial market declined 67% or $711 thousand, influenced by a large FY 2025 European glass coating order that did not repeat.
Geography: US/Canada sales decreased 5% y-o-y, or $324 thousand, driven by slowing momentum in the US clean energy industry. This was offset by increased sales in Asia with 74% growth y-o-y, or $647 thousand, led by strong medical sales in China and strong alternative energy sales in Japan and South Korea. EMEA sales declined slightly, declining $60 thousand and Latin American sales down $160 thousand, due to slow fluxing sales in Mexico. Balance Sheet and Cash Flow Overview

At August 31, 2025, cash, cash equivalents and marketable securities totaled $10.6 million, with no debt, and stockholders’ equity was $18.7 million.

Capital expenditures in the first half of fiscal 2026 were $113K, which were invested in ongoing upgrades to the Sono-Tek’s manufacturing facilities. Sono-Tek anticipates that capital expenditures will total approximately $300k in fiscal year 2026.

Conference Call Information

Sono-Tek will hold a conference call to discuss its second quarter and first half of fiscal year 2026 financial results today, Tuesday, October 14, 2025 at 10:30 am ET. To participate, please call 1-844-481-2752 or 1-412-317-0668 for international callers at least 10 minutes prior to the start of the call and ask to join the Sono-Tek call.

A simultaneous webcast of the call may be accessed through the Company's website, Events & Presentations | Sono-Tek or at https://event.choruscall.com/mediaframe/webcast.html?webcastid=L9LSqRTH

A replay of the call will be available at 1-877-344-7529 or 1-412-317-0088 for international callers, access code 6867548, through October 21, 2025. A replay of the call will also be available on the Company’s website for one year at www.sono-tek.com.

About Sono-Tek

Sono-Tek Corporation (Nasdaq: SOTK) is a global leader in the design and manufacture of ultrasonic coating systems that are shaping industries and driving innovation worldwide. Our ultrasonic coating systems are used to apply thin films onto parts in diverse industries including medical devices, semiconductors, microelectronics, alternative energy, advanced industrial manufacturing, and research and development sectors.

Sono-Tek has a long history of providing advanced coating solutions to the medical device industry, enabling precision coatings for life-saving technologies such as stents, balloons, diagnostic devices, and various drug delivery platforms. At the same time, our expertise in semiconductor and microelectronics applications continues to expand, as customers increasingly turn to Sono-Tek for solutions supporting next-generation chips, displays, and sensors. Alongside these markets, our technologies are also leading the way in next-generation clean energy coatings for fuel cells, carbon capture, advanced solar cells, and various other advanced industrial applications, underscoring the versatility and broad reach of Sono-Tek’s ultrasonic coating platforms.

Our product line is rapidly evolving, transitioning from R&D tools to high-volume production machines with significantly higher average selling prices, showcasing our market leadership and adaptability. Our comprehensive suite of thin film coating solutions and application consulting services ensures unparalleled results for our clients and helps some of the world’s most promising companies achieve technological breakthroughs and bring them to market. The company strategically delivers its products to customers through a network of direct sales personnel, carefully chosen independent distributors, and experienced sales representatives, ensuring efficient market reach across diverse sectors around the globe.

Our growth strategy is focused on leveraging our innovative technologies, proprietary know-how, unique talent and experience, and global reach to further develop microscopic coating technologies that enable better outcomes for our customers’ products and processes. For further information, visit www.sono-tek.com.

Safe Harbor Statement

This news release contains forward looking statements regarding future events and the future performance of Sono-Tek Corporation that involve risks and uncertainties that could cause actual results to differ materially. These “forward-looking statements’ are based on currently available competitive, financial and economic data and our operating plans. They are inherently uncertain, and investors must recognize that events could turn out to be significantly different from our expectations and could cause actual results to differ materially. These factors include, among other considerations, general economic and business conditions, including political, regulatory, tax, competitive and technological developments affecting our operations or the demand for our products; inflationary and supply chain pressures; continued strength of sales to the medical device market; continued private and public funding for the clean energy sector and continued strong demand for Sono-Tek’s suite of thin film coating solutions and application consulting services in the clean energy and other markets; maintenance of order backlog; the imposition of tariffs; timely development and market acceptance of new products and continued customer validation of our coating technologies; adequacy of financing; capacity additions, the ability to enforce patents; maintenance of operating leverage; consummation of order proposals; completion of large orders on schedule and on budget; successful transition from primarily selling ultrasonic nozzles and components to a more complex business providing complete machine solutions and higher value subsystems; and realization of quarterly and annual revenues within the forecasted range of sales guidance. We undertake no obligation to update any forward-looking statement.

For more information:

Sono-Tek Corp.
Stephen J. Bagley
Chief Financial Officer
Ph: (845) 795-2020
[email protected]

Investor Relations
Kirin Smith
PCG Advisory, Inc.
[email protected]

 -FINANCIAL TABLES FOLLOW-

SONO-TEK CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS   August 31,
2025  February 28,
2025   (Unaudited)    ASSETS                 Current Assets:        Cash and cash equivalents $3,832,133  $5,202,361 Marketable securities  6,736,469   6,727,678 Accounts receivable (less allowance of $12,225, respectively)  4,212,354   2,347,764 Inventories  4,152,027   4,474,401 Prepaid expenses and other current assets  188,695   236,261 Total current assets  19,121,678   18,988,465          Land  250,000   250,000 Buildings, equipment, furnishings and leasehold improvements, net  2,413,664   2,610,600 Intangible assets, net  33,529   37,386 Deferred tax asset  1,366,864   1,525,185          TOTAL ASSETS $23,185,735  $23,411,636          LIABILITIES AND STOCKHOLDERS’ EQUITY                 Current Liabilities:        Accounts payable $614,512  $859,483 Accrued expenses  1,852,959   1,718,574 Customer deposits  1,906,629   2,413,195 Income taxes payable  27,813   496,055 Total current liabilities  4,401,913   5,487,307          Deferred tax liability  88,153   132,134 Total liabilities  4,490,066   5,619,441          Commitments and Contingencies (Note 10)                 Stockholders’ Equity        Common stock, $.01 par value; 25,000,000 shares authorized, 15,751,153 issued and 15,707,062 outstanding as of August 31, 2025 and 15,751,153 issued and 15,749,037 outstanding February 28, 2025, respectively  157,512   157,512 Additional paid-in capital  10,163,952   10,018,034 Accumulated earnings  8,533,194   7,624,516 Treasury stock, at cost, 44,091 shares and 2,116 shares, August 31, 2025 and February 28, 2025, respectively  (158,989)  (7,867)Total stockholders’ equity  18,695,669   17,792,195          TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $23,185,735  $23,411,636   See notes to unaudited condensed consolidated financial statements. SONO-TEK CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)   Six Months Ended
August 31,  Three Months Ended
August 31,   2025  2024  2025  2024              Net Sales $10,295,469  $10,192,820  $5,162,696  $5,161,782 Cost of Goods Sold  5,041,218   5,222,236   2,572,959   2,645,685 Gross Profit  5,254,251   4,970,584   2,589,737   2,516,097                  Operating Expenses                Research and product development costs  1,295,748   1,427,303   627,278   695,873 Marketing and selling expenses  1,729,504   1,885,608   871,353   988,418 General and administrative costs  1,324,477   1,133,387   669,952   545,816 Total Operating Expenses  4,349,729   4,446,298   2,168,583   2,230,107                  Operating Income  904,522   524,286   421,154   285,990                  Interest and Dividend Income  223,660   227,730   81,562   85,076 Net unrealized gain on marketable securities  1,570   53,941   23,493   43,580                  Income Before Income Taxes  1,129,752   805,957   526,209   414,646                  Income Tax Expense  221,074   134,435   102,516   73,961                  Net Income $908,678  $671,522  $423,693  $340,685                  Basic Earnings Per Share $0.06  $0.04  $0.03  $0.02                  Diluted Earnings Per Share $0.06  $0.04  $0.03  $0.02                  Weighted Average Shares - Basic  15,727,844   15,750,895   15,721,162   15,750,910 Weighted Average Shares - Diluted  15,740,384   15,771,472   15,731,571   15,768,251  See notes to unaudited condensed consolidated financial statements.  Product Sales

  Three Months Ended
August 31,  Change  Six Months Ended
August 31,  Change   2025  2024  $  %  2025  2024  $  % Fluxing Systems $165,000  $119,000   46,000   39%  $317,000  $253,000   64,000   25% In-Line Coating Systems 1  1,530,000   2,023,000   (493,000)   (24%)  4,584,000   2,770,000   1,814,000   65% Multi-Axis Coating Systems  2,030,000   1,931,000   99,000   5%   2,707,000   4,595,000   (1,888,000)   (41%) OEM Systems  394,000   205,000   189,000   92%   524,000   537,000   (13,000)   (2%) Spare Parts, Services and Other  1,044,000   884,000   160,000   18%   2,164,000   2,038,000   126,000   6% TOTAL $5,163,000  $5,162,000   1,000   0%  $10,296,000  $10,193,000   103,000   1%  During the current reporting period, the Company updated the title of its product category previously referred to as “Integrated Coating Systems” to “In-Line Coating Systems.” This change was made to provide greater clarity in describing this product line of our business. The definition and contents of this category remain unchanged. In-Line Coating Systems include Sono-Tek products that are typically stationary platforms with minimal motion control, and may occasionally incorporate a simple axis of movement such as a rotation fixture. These systems are commonly installed over moving substrates such as conveyors or webs, which may be provided either by Sono-Tek or by the customer. They often employ multiple ultrasonic nozzles to provide uniform coverage over larger areas in continuous production environments. In-Line Coating Systems are unlike our Multi-Axis Coating Systems, which commonly utilize XYZ motion platforms or 6+ axis robotic configurations. Market Sales

  Three Months Ended
August 31,  Change  Six Months Ended
August 31,  Change   2025  2024  $  %  2025  2024  $  % Electronics/Microelectronics $1,455,000  $1,477,000   (22,000)  (1%) $2,399,000  $3,045,000   (646,000)  (21%)Medical  1,004,000   402,000   602,000   150%   1,812,000   1,259,000   553,000   44% Alternative/Clean Energy  2,433,000   2,498,000   (65,000)  (3%)  5,681,000   4,780,000   901,000   19% Emerging R&D and Other  33,000   30,000   3,000   10%   47,000   41,000   6,000   15% Industrial  238,000   755,000   (517,000)  (68%)  357,000   1,068,000   (711,000)  (67%)TOTAL $5,163,000  $5,162,000   1,000   0%  $10,296,000  $10,193,000   103,000   1%   Geographic Sales

  Three Months Ended
August 31,  Change  Six Months Ended
August 31,  Change   2025  2024  $  %  2025  2024  $  % U.S. & Canada $2,720,000  $3,495,000   (775,000)  (22%) $6,263,000  $6,587,000   (324,000)  (5%)Asia Pacific (APAC)  930,000   368,000   562,000   153%   1,527,000   880,000   647,000   74% Europe, Middle East, Asia (EMEA)  1,424,000   1,136,000   288,000   25%   2,321,000   2,381,000   (60,000)  (3%)Latin America  89,000   163,000   (74,000)  (45%)  185,000   345,000   (160,000)  (46%)TOTAL $5,163,000  $5,162,000   1,000   0%  $10,296,000  $10,193,000   103,000   1%  

CNBC's Phil LeBeau joins 'Squawk Box' with the latest news from General Motors.

The deal will create a combined company with an enterprise value of more than $8 billion.

Analyst’s Disclosure:I/we have a beneficial long position in the shares of PLTR either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

October 14, 2025 07:18 ET

 | Source:

Atlas Salt Inc.

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

ST. GEORGE'S, Newfoundland and Labrador, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Atlas Salt Inc. (“Atlas Salt” or the “Company”) (TSXV: SALT; OTCQB: REMRF; FRA:9D00) announces that it has entered into an agreement with Raymond James Ltd. and Ventum Financial Corp. (collectively, the “Agents”), to act as co-leads and joint bookrunners, in connection with a commercially reasonable efforts private placement offering for up to 10,000,000 common shares of the Company (“Common Shares”) at a price of $0.80 per Common Share (“Offering Price”) for aggregate gross proceeds of up to $8,000,000 (the “Offering”).

The Company has also granted the Agents an option (the “Agents’ Option”) to sell up to an additional 1,500,000 Common Shares for additional gross proceeds of up to $1,200,000, exercisable in whole or in part, any time up to 48 hours prior to the closing of the Offering. The Agents shall be under no obligation, in whole or in part, to exercise the Agents’ Option.

The Company has agreed to pay to the Agents a cash commission equal to 6% of the gross proceeds of the Offering. The Company has also agreed to issue to the Agents that number of compensation options (“Compensation Options”) equal to 6.0% of the aggregate number of Shares issued by the Company under the Offering. Each Compensation Option is exercisable to acquire one Common Share at a price equal to the Offering Price for a period of 24 months from the closing date of the Offering.

Subject to compliance with applicable regulatory requirements and in accordance with National Instrument 45-106 - Prospectus Exemptions (“NI 45-106”), the Offering will be offered for sale to purchasers resident in all of the provinces of Canada with the exception of Québec pursuant to the listed issuer financing exemption under Part 5A of NI 45-106, as amended by Coordinated Blanket Order 45-935 - Exemptions from Certain Conditions of the Listed Issuer Financing Exemption (the “Listed Issuer Financing Exemption”). The securities issuable from the sale of the Offering are expected to be immediately freely tradeable in accordance with applicable Canadian securities legislation if sold to purchasers resident in Canada. The Common Shares may also be sold in offshore jurisdictions and in the United States on a private placement basis pursuant to one or more exemptions from the registration requirements of the United States Securities Act of 1933, as amended (the “U.S. Securities Act”). The minimum amount to be raised in the offering is $5,000,000.

There is an offering document (the “Offering Document”) related to the Offering that can be accessed under the Company's profile at www.sedarplus.ca and on the Company’s website at www.atlassalt.com. Prospective investors should read this Offering Document before making an investment decision.

The net proceeds received from the Offering will be used for civil engineering work related to advancing the Great Atlantic Salt Project towards development and for general corporate and working capital purposes, as further described in the Offering Document.

The Offering is scheduled to close on or about October 21, 2025 (“Closing Date”) or such other date as the Company and the Agents may agree and, in any event, on or before a date not later than 45 days after the date of the news release announcing the Offering. Completion of the Offering is subject to certain conditions including, but not limited to, the receipt of all necessary approvals, including the approval of the TSX Venture Exchange.

Certain insiders of the Company are anticipated to participate in the Offering, and such participation by insiders will constitute a related party transaction as defined in Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The Company intends to rely on exemptions from the formal valuation and minority shareholder requirements provided under sections 5.5(a) and 5.7(1)(a) of MI 61-101 on the basis that neither the fair market value of the securities to be issued under the Offering nor the consideration to be paid by insiders of the Company will exceed 25% of the Company's market capitalization.

This news release does not constitute an offer to sell or a solicitation of an offer to sell any securities in the United States. The securities have not been and will not be registered under the U.S. Securities Act or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

About Atlas Salt

Atlas Salt is developing Canada’s next salt mine and is committed to responsible and sustainable mining practices. With a focus on innovation and efficiency, the company is poised to make significant contributions to the North American salt market while upholding its values of environmental stewardship and community engagement.

For information, please contact:

Jeff Kilborn, CFO & VP Corporate Development
[email protected]
(709) 275-2009

We seek safe harbour.

Cautionary Statement

Neither the TSX Venture Exchange nor its Regulation Services Provider (as the term is defined in the Policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This press release includes certain “forward-looking information” and “forward-looking statements” (collectively “forward-looking statements”) within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein, without limitation, statements relating to the future operating or financial performance of the Company, are forward-looking statements. Forward-looking statements are frequently, but not always, identified by words such as “expects”, “anticipates”, “believes”, “intends”, “estimates”, “potential”, “possible”, and similar expressions, or statements that events, conditions, or results “will”, “may”, “could”, or “should” occur or be achieved. Forward-looking statements in this press release relate to the anticipated closing of the Offering; the approval of the TSX Venture Exchange; the filing of the Offering Document; the intended use of proceeds from the Offering. Actual future results may differ materially. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates that, while considered reasonable by the respective parties, are inherently subject to significant business, technical, economic, and competitive uncertainties and contingencies. Many factors, both known and unknown, could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements and the parties have made assumptions and estimates based on or related to many of these factors. Such factors include, without limitation: the timing, completion and delivery of required permits, supply arrangements and financing. Readers should not place undue reliance on the forward-looking statements and information contained in this news release concerning these times. Except as required by law, the Company does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

October 14, 2025 6:00 AM EDT | Source: Loncor Gold Inc.
Toronto, Ontario--(Newsfile Corp. - October 14, 2025) - Loncor Gold Inc. (TSX: LN) (OTCQX: LONCF) (FSE: LO5) ("Loncor" or the "Company") and Chengtun Mining Group Co., Ltd. (SSE: 600711), Ltd, through its wholly-owned subsidiary, Chengtun Gold Ontario Inc. (collectively "Chengtun Mining" or the "Purchaser"), are pleased to announce they have entered into an arrangement agreement (the "Arrangement Agreement"), pursuant to which Chengtun Mining will acquire all the outstanding common shares of Loncor (each, a "Loncor Share"), in exchange for C$1.38 per Loncor Share (the "Consideration") in an all-cash transaction by way of a plan of arrangement (the "Transaction"). The Consideration represents total equity value of approximately C$261 million on a fully diluted basis.

The Consideration represents a premium of approximately 33% to the 30-day volume weighted average trading price ("VWAP") of the Loncor Shares, and a premium of approximately 16% to the closing price of the Loncor Shares as at October 10, 2025 on the Toronto Stock Exchange (the "TSX"). Further details of the Transaction are outlined below.

As part of the Transaction, Loncor shareholders representing approximately 38% of the issued and outstanding Loncor Shares have signed voting support agreements, pursuant to which they have agreed, among other things, to vote their Loncor Shares in favour of the Transaction.

Arnold Kondrat, Executive Chairman of Loncor, commented: "I am pleased to announce that we have entered into an agreement for the sale of the Company, marking a significant achievement for all stakeholders. This Transaction crystallizes the inherent value we have built over 15 years and eliminates future dilution while mitigating commodity, political, and execution risks. The sale delivers a strong outcome for shareholders."

Transaction Highlights

Immediate and significant premium of approximately 33% and 16% to the 30-day VWAP and the closing price of the Loncor Shares, respectively. All-cash offer, providing certainty of value and immediate liquidity to Loncor shareholders. Highly capable counterparty in Chengtun Mining which is principally engaged in trading and mining of new energy metal business internationally. Chengtun Mining's products mainly include copper, cobalt, nickel and gold, and has accumulated extensive operational experience in the Democratic Republic of the Congo.Crystallizes value while removing future dilution, commodity and execution risk for Loncor shareholders. Leverage's Chengtun Mining's strong access to capital and depth of technical and in-country expertise to develop the Imbo project. Transaction Terms

Pursuant to the terms and conditions of the Arrangement Agreement, signed on October 14, 2025, the holders of the issued and outstanding Loncor Shares will receive the Consideration. The Transaction will be carried out by way of court-approved plan of arrangement under the Business Corporations Act (Ontario).

The Arrangement Agreement contains customary reciprocal deal-protection provisions including a non-solicitation covenant and a "fiduciary out" that would allow Loncor to accept a superior proposal as defined in the Arrangement Agreement, subject to a right for Chengtun Mining to match any superior proposal. The Arrangement Agreement also provides for a mutual reciprocal termination fee of C$10 million, payable in certain circumstances.

Pursuant to the Arrangement Agreement, each outstanding Loncor stock option and Loncor common share purchase warrant outstanding at the effective time of the Transaction, will be deemed to be surrendered, assigned and transferred by the holder thereof to Loncor in exchange for a cash payment equal to the amount by which the Consideration exceeds the exercise price of such stock option or warrant, as applicable.

The Arrangement Agreement also provides that the Purchaser will provide to Loncor refundable advances totalling US$3,000,000 within the 60 day period following the date of the Arrangement Agreement. These advances are to be used in connection with the Company's ongoing exploration program at the Adumbi deposit and for general corporate purposes.

Further details of the Arrangement Agreement will be included in a management information circular of Loncor that is expected to be mailed to Loncor shareholders in the coming weeks. A copy of the Arrangement Agreement will be made available on Loncor's SEDAR+ profile at www.sedarplus.ca.

Conditions to Completion

The completion of the Transaction is subject to a number of terms and conditions, including without limitation the following: (i) approval of the Loncor shareholders, as described below; (ii) acceptance of the TSX; (iii) approval of the Ontario Superior Court; and (iv) other standard conditions of closing for a transaction of this nature. There can be no assurance that all of the necessary approvals will be obtained or that all conditions of closing will be satisfied.

The Transaction is subject to the approval at a special meeting of Loncor shareholders (the "Loncor Meeting") by: (a) 66 2/3 percent of the votes cast by Loncor shareholders; and (b) a majority of the votes cast by the Loncor shareholders (excluding the votes cast by persons whose votes may not be included in determining minority approval of a "business combination" in accordance with Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions).

Transaction Timeline

Subject to certain conditions, including the parties obtaining the requisite regulatory approvals, the Transaction is expected to close not later than Q1 2026. Following completion of the Transaction, the Loncor Shares are expected to be de-listed from the TSX. Loncor will also apply to cease to be a reporting issuer under Canadian securities laws and a registrant with the United States Securities and Exchange Commission (the "SEC").

Voting Support Agreements

Each director and officer of Loncor, and Loncor's largest shareholders, Resolute Mining Ltd, and Arnold Kondrat (Executive Chairman of Loncor), who own approximately 18% and 17%, respectively, of the issued and outstanding Loncor Shares, have entered into a voting support agreement with Chengtun Mining pursuant to which they have agreed to vote their respective Loncor Shares in favour of the Transaction at the Loncor Meeting.

Loncor Board of Directors' and Special Committee Recommendations

After consultation with its financial and legal advisors, and following the unanimous recommendation of a special committee of independent directors (the "Special Committee"), the board of directors of Loncor (the "Loncor Board") unanimously determined the Transaction is fair to Loncor shareholders, is in the best interest of Loncor and approved the entering into of the Transaction. The Loncor Board recommends that Loncor shareholders vote in favour of the Transaction. Stifel Canada provided a fairness opinion to the Special Committee, stating that, as of the date of such opinion and based upon and subject to the assumptions, limitations and qualification stated in such opinion, the Consideration to be received by Loncor shareholders under the Transaction is fair, from a financial point of view, to such Loncor shareholders. The fairness opinion provided by Stifel Canada will be included in the circular mailed to Loncor shareholders.

Advisors and Counsel

Stifel Canada and EB Capital Advisory are acting as financial advisors to Loncor and the Loncor Board. Dickinson Wright LLP are acting as Loncor's legal counsel. Baker McKenzie FenXun acted as international counsel to Chengtun Mining and Dentons Canada LLP acted as Canadian counsel to Chengtun Mining.

About Loncor Gold Inc.

Loncor is a Canadian gold exploration company focused on the Ngayu Greenstone Gold Belt in the northeast of the Democratic Republic of the Congo (the "DRC"). The Loncor team has over two decades of experience of operating in the DRC. Loncor's growing resource base in the Ngayu Belt is focused on the Imbo Project where the Adumbi deposit holds an indicated mineral resource of 1.88 million ounces of gold (28.185 million tonnes grading 2.08 g/t gold), and the Adumbi deposit and two neighbouring deposits hold an inferred mineral resource of 2.090 million ounces of gold (22.508 million tonnes grading 2.89 g/t Au), with 84.68% of these resources being attributable to Loncor. Following a drilling program carried out by the Company at the Adumbi deposit in 2020 and 2021, the Company completed a Preliminary Economic Assessment ("PEA") of the Adumbi deposit and announced the results of the PEA in December 2021.

Additional information with respect to Loncor and its projects can be found on Loncor's website at www.loncor.com.

About Chengtun Mining Group Co., Ltd.

Chengtun Mining specializes in developing new energy metal resources. The company's core operations include mining and refining of energy metals and base metals, with strategic focus on copper, cobalt, nickel for new energy batteries. The company has also identified gold and other precious metals as a key strategic business area for future development. Chengtun owns and operates mines in the Democratic Republic of the Congo, most notably the Kalongwe copper-cobalt mine. Chengtun Mining is publicly listed on the Shanghai Stock Exchange under the ticker 600711.

Cautionary Note Concerning Forward-Looking Information

This press release contains forward-looking information. All statements, other than statements of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding completion of the terms and conditions of the Transaction, receipt of Loncor shareholder and court approval of the Transaction, the Purchaser advancing funds to the Company, disclosure in the Company's management information circular, the expected closing date of the Transaction, the Company ceasing to be a reporting issuer in Canada and a registrant with the SEC in the United States and the delisting of the Loncor Shares) are forward-looking information. This forward-looking information reflects the current expectations or beliefs of the Company based on information currently available to the Company. Forward-looking information is subject to a number of risks and uncertainties that may cause the actual results of the Company to differ materially from those discussed in the forward-looking information, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on the Company. Factors that could cause actual results or events to differ materially from current expectations include, among other things, risks associated with the possibility that the Transaction will not be completed on the terms and conditions, or on the timing, currently contemplated, and that it may not be completed at all, due to a failure to obtain or satisfy, in a timely manner or otherwise, required shareholder, court and regulatory approvals and other conditions of closing necessary to complete the Transaction or for other reasons, the possibility of adverse reactions or changes in business relationships resulting from the announcement or completion of the Transaction, risks relating to the abilities of the parties to satisfy conditions precedent to the Transaction, a third party superior proposal materializing prior to the completion of the Transaction and the other risks disclosed under the heading "Risk Factors" and elsewhere in the Company's annual information form dated March 31, 2025 filed on SEDAR+ at www.sedarplus.ca and EDGAR at www.sec.gov. Forward-looking information speaks only as of the date on which it is provided and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise. Although the Company believes that the assumptions inherent in the forward-looking information are reasonable, forward-looking information is not a guarantee of future performance and accordingly undue reliance should not be put on such information due to the inherent uncertainty therein.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/270343

- Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne vulgaris compared with placebo in a Phase III randomized, double-blind, placebo-controlled, multicenter clinical trial. HONG KONG , Oct. 14, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that it recently completed the pre-New Drug Application (NDA) consultation with China National Medical Products Administration (NMPA) for denifanstat (ASC40) for the treatment of moderate-to-severe acne vulgaris and plans to submit an NDA soon.